Nancy A. Simonian
Presently, Nancy A. Simonian is President, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc. She is also on the board of Seagen Inc., Biotechnology Innovation Organization and The Damon Runyon Cancer Research Foundation.
She previously held the position of Vice President-Clinical Development at Biogen, Inc., Chief Medical Officer & SVP-Regulatory Affairs at Millennium Pharmaceuticals, Inc., Faculty Member at The General Hospital Corp., Assistant Professor at Massachusetts General Hospital Cancer Center and Assistant Professor at Harvard Medical School.
Dr. Simonian received an undergraduate degree from Princeton University, a doctorate from Perelman School of Medicine and a doctorate from the University of Pennsylvania Medical Center.
|04/01/2022||58,883||Derivative/Non-derivative trans. at $1.12 per share.||65,949|
|12/18/2020||4,988||Derivative/Non-derivative trans. at $10.09 per share.||50,328|
|12/18/2020||14,168||Derivative/Non-derivative trans. at $8.51 per share.||120,569|
|12/18/2020||10,761||Derivative/Non-derivative trans. at $3.04 per share.||32,713|
|12/23/2019||52,401||Derivative/Non-derivative trans. at $3.04 per share.||159,299|
|02/12/2019||188,000||Award at $0 per share.||0|
|11/29/2018||12,084||Derivative/Non-derivative trans. at $3.04 per share.||36,735|
|11/29/2018||98,504||Derivative/Non-derivative trans. at $1.01 per share.||99,489|